Company

The Company’s core assets are natural product classes and their synthetic analogues comprising a product platform with multiple partnering and development opportunities. The compound classes show a extremely potent biological activity profile against tubulin and are predominantly useful for novel therapeutic approaches in oncology. Especially the ability to conjugate the highly active compounds with any kind of delivery technology or targeting principles offers strong development opportunities towards more efficacious and safer products.